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Impact of Body Mass Index on COVID-19-Related In-
Hospital Outcomes and Mortality
Waqas Ullaha, d, Sohaib Roomia, Nayab Nadeema, Rehan Saeedb, Shafaq Tariqa, Moataz Ellithib, 
 Shujaul Haqa, Ahmad Arslana, John Madaraa, Margot Boigona, 
 Donald C. Haasa, David L. Fischmanc
Abstract
Background: Given the high prevalence of obesity around the globe, 
patients with coronavirus disease 2019 (COVID-19) are at an in-
creased risk of devastating complications.
Methods: A retrospective cohort study was performed to determine 
the association of basal metabolic index (body mass index (BMI)) 
with the need for invasive mechanical ventilation (IMV), dialysis, 
upgrade to an intensive care unit (ICU) and mortality. Independent 
t-test and multivariate logistic regression analysis were performed to 
calculate mean differences and adjusted odds ratios (aORs) with its 
95% confidence interval (CI), respectively.
Results: A total of 176 consecutive patients with confirmed COVID-19 
diagnosis were included. The mean age was 62.2 years, with 51% be-
ing male patients. The mean BMI for non-surviving patients was sig-
nificantly higher compared to patients surviving on the seventh day of 
hospitalization (35 vs. 30 kg/m2, P = 0.022). Similarly, patients requir-
ing IMV had a higher BMI (33 vs. 29, P = 0.002) compared to non-
intubated patients. The unadjusted OR for patients with a higher BMI 
requiring IMV (56% vs. 28%, OR: 3.3, 95% CI: 1.6 - 7.0, P = 0.002) 
and upgrade to ICU (46% vs. 28%, OR; 2.2, 1.07 - 4.6, P = 0.04) were 
significantly higher compared to patients with a lower BMI. Similarly, 
patients with a higher BMI had higher in-hospital mortality (21% vs. 
9%, OR: 3.2, 95% CI: 1.3 - 8.2, P = 0.01) compared to patients with a 
normal BMI. Despite a numerical advantage in the lower BMI group, 
there was no significant difference between the two groups in terms of 
the need for dialysis (5% vs. 13%, OR: 3.8, 13% vs. 4%, 1.1 - 14.1, P 
= 0.07). aORs controlled for baseline comorbidities and medications 
mirrored the overall results, except for the need to upgrade to ICU.
Conclusions: In patients with confirmed COVID-19, morbid obesity 
serves as an independent risk factor of high in-hospital mortality and 
the need for IMV.
Keywords: Body mass index; COVID-19; In-hospital mortality; In-
vasive mechanical ventilation
Introduction
The USA is the current epicenter of the novel coronavirus pan-
demic with over 1.6 million cases and nearly 100,000 deaths. 
While the true mortality and morbidity caused by coronavirus 
disease 2019 (COVID-19) will take years to become appar-
ent, we do know that certain groups of people particularly the 
elderly and those with certain comorbidities are at a signifi-
cantly higher risk of worse outcomes. Among these conditions 
is obesity, with the USA currently leading the developed world 
in terms of obesity among its citizens (42%), this puts a large 
population at measurably higher risk of major complications, 
delayed recovery and potentially higher mortality [1, 2].
An analysis of a large cohort of COVID-19 patients by 
Lighter et al demonstrated 1.8 and 3.6 times greater probabil-
ity for admission to critical care units for obese (body mass 
index (BMI) 30 - 34.9) and morbidly obese patients (BMI > 
35), respectively [3]. Similarly, in a study by Kalligeros et al 
and Petrilli et al, BMI ≥ 35 kg/m2 was associated with a sig-
nificantly higher rate of admission to intensive care unit (ICU) 
and need for invasive mechanical ventilation (IMV) [4, 5].
With a high burden of COVID19 and limited healthcare 
resources, it is imperative to determine the impact of obesity 
not only on in-hospital complications but also on mortality, to 
better inform clinical decision making and resource allocation.
Materials and Methods
Study design and participants
This retrospective cohort study included consecutive adult 
inpatients (≥ 18 years old) from Abington Hospital, Jefferson 
Health, Pennsylvania, USA. All patients had a confirmed di-
agnosis of COVID-19 between March 1, 2020, and May 10, 
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2020. The study was approved by the Institutional Review 
Board (IRB) and the requirement for informed consent was 
waived by the Research Ethics Committee (REC). All proce-
dures described in the study have been actuated according to 
ethical principles for medical research involving human sub-
ject stated in the Declaration of Helsinki.
Data collection
Clinical, demographic, laboratory, treatment, and outcome data 
were extracted from electronic medical records (Sunrise) using 
a standardized data collection form. All authors contributed to 
data retrieval and an independent author adjudicated any dif-
ference in interpretation between the data extractors. Severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) de-
tection in respiratory specimens (throat swabs) was done by 
next-generation sequencing or real-time qualitative polymer-
ase chain reaction (RT-qPCR) methods. The laboratory val-
ues, cut-off variables and methods for laboratory confirmation 
of SARS-CoV-2 infection were standardized. Data regarding 
baseline comorbidities included a history of diabetes mellitus 
(DM), hypertension (HTN), chronic kidney disease (CKD) and 
coronary artery disease (CAD). In hospital medications used 
included hydroxychloroquine (HCQ), tocilizumab, steroids and 
anticoagulation (AC). Routine blood work included coagulation 
profile, complete blood count, serum biochemical tests (renal 
function, C-reactive protein (CRP), D-dimer, lactate dehydroge-
nase (LDH), myocardial enzymes (troponin T (TnT)) and serum 
ferritin. Chest radiographs or computed tomography (CT) scans 
were also done for most inpatients where clinically indicated. 
The criteria for discharge were absence of fever, freedom from 
symptoms, and substantial clinical or radiological improvement 
for at least 1 day.
Based on the standard definition of the World Health Or-
ganization (WHO), patients were divided into two groups, 
severely obese population with a BMI > 35 kg/m2 and those 
who were not severely obese (BMI < 34.9 kg/m2). Patients 
with BMI 18.5 - 24.9 kg/m2 were classified as having a normal 
BMI, and those with BMI greater than 40 kg/m2 were noted as 
very severely obese.
Statistical analysis
Continuous variables were presented as mean and standard 
deviation (SD); categorical variables were reported in percent-
ages and proportions. A Chi-square (χ2) test was used for com-
parison of categorical data. Fisher exact test was only adopted 
if the expected count in more than 20% cells was less than 
5. To quantify the association between the dichotomous cat-
egorical variables, an unadjusted odds ratio (OR) was obtained 
using the Cochran-Mantel-Haenszel method. To explore the 
risk factors and gauge the impact of potential effect modifiers 
(covariates) on our endpoints (in-hospital death, need for an 
upgrade, ventilators and dialysis) binomial and multinomial 
logistic regression models were applied as appropriate. The 
differences in the baseline comorbidities (DM, HTN, CAD, 
CKD) and medication use (HCQ, tocilizumab, AC and ster-
oids) were accounted for to obtain an adjusted OR (aOR) for 
all outcomes. The Hosmer-Lemeshow (HL) goodness-of-fit 
test was used to predict the fitness of logistic regression models 
for applicability to categorical data. The mean BMI values for 
baseline comorbidities, in-hospital complications and clinical 
endpoints were also compared for both comparison groups. For 
normally and abnormally distributed continuous data, an inde-
pendent sample t-test and Mann-Whitney U test were utilized, 
respectively. A one-way analysis of variance (ANOVA) was 
used to compare differences in the mean of continuous vari-
ables for multiple in-hospital complications. A two-sided α of 
less than 0.05 was considered statistically significant corrobo-
rating inference from a 95% confidence interval (CI). Statistical 
analyses were performed using the SPSS software (version 25).
Results
Demographics and baseline characteristics
A total of 176 consecutive patients (137 with BMI < 34.9 and 
39 with BMI > 35) were included. The mean age for lower 
BMI vs. higher BMI groups was 64.8 vs. 62.6 (P = 0.02), re-
spectively. The baseline comorbidities across all groups were 
comparable except that the lower BMI group had a higher per-
centage of chronic obstructive pulmonary disease (COPD) (P 
= 0.01) and DM (0.046). The proportion of other comorbidi-
ties and medication use (HCQ, tocilizumab, AC, steroids) were 
comparable across both groups (P ≥ 0.05) (Fig. 1 and Table 1).
Mean differences in BMI across outcomes
The mean BMI for patients who were alive (153/176) at the 
7-day of hospitalization was 30.2 ± 8.9 compared to a BMI 
of 35.4 ± 13.8 for patients who died (23/176). The mean dif-
ference of BMI was -5.15 (95% CI: -9.5 to -7.4), significantly 
lower in patients who were alive (P = 0.022). Similarly, 60/176 
patients who were intubated had a higher BMI of 33.9 ± 11.2 
compared to non-intubated patients (n = 116/176, BMI: 29.2 ± 
8.4). The mean difference in the BMI was significantly low-
er in the non-ventilated group (-4.7 (-7.7 to -1.7) P = 0.002). 
There was no significant difference in the BMI of patients re-
ceiving HCQ vs. no HCQ (P = 0.21), tocilizumab vs. no toci-
lizumab (P = 0.44), or AC (P = 0.14). Similarly, a higher BMI 
was not associated with an increased risk of new-onset kidney 
failure requiring dialysis (P = 0.29) or an upgrade to the critical 
care unit (P = 0.14) (Fig. 2, Table 2).
The incidence of in-hospital COVID-19 related compli-
cations was rare and not significantly impacted by BMI (P = 
0.65). The mean BMI for patients developing deep vein throm-
bosis (DVT), pulmonary embolism (PE), sepsis, acute kidney 
injury (AKI), atrial fibrillation (AF), junctional rhythm and 
bleeding was 24.50 ± 2.12 kg/m2, 30.33 ± 5.51 kg/m2, 27.89 
± 14.87 kg/m2, 38.27 ± 17.70 kg/m2, 31.50 ± 6.32 kg/m2 and 
21.0 kg/m2, respectively. Intriguingly, the BMI for the patient 
developing cardiac arrest and AF was 52 kg/m2 (Supplementa-
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Table 1.  Baseline Characteristics of the Included Population Across Comparison Groups
BMI < 34.9 BMI > 35 P value
Male 76 (88.4%) 10 (11.6%) 0.001*
Female 61 (67.8%) 29 (32.2%)
CAD 24 (77.4%) 7 (22.6%) 0.95
COPD 14 (58.3%) 10 (41.7%) 0.013*
CKD 22 (68.8%) 10 (31.3%) 0.171
HTN 85 (74.6%) 29 (25.4%) 0.155
DM 43 (69.4%) 19 (30.6%) 0.046*
Tocilizumab 23 (71.9%) 9 (28.1%) 0.369
HCQ 109 (75.7%) 35 (24.3%) 0.146
Steroids 19 (63.3%) 11 (36.7%) 0.036*
AC 23 (67.6%) 11 (32.4%) 0.111
*P < 0.05. BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; HTN: 
hypertension; DM: diabetes mellitus; HCQ: hydroxychloroquine; AC: anticoagulation.
Figure 1. Baseline characteristics of patients in different groups. CAD: coronary artery disease; COPD: chronic obstructive 
pulmonary disease; CKD: chronic kidney disease; HTN: hypertension; DM: diabetes mellitus; HCQ: hydroxychloroquine; AC: 
anticoagulation.
Figure 2. Forest plots comparing in-hospital endpoints across high and lower BMI groups. BMI: body mass index.
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ry Material 1, www.jocmr.org). Similarly, there was no signifi-
cant difference in the mean values of inflammatory markers 
and laboratory investigations of patients with higher and lower 
BMI (Supplementary Material 2, www.jocmr.org).
ORs of outcomes
The unadjusted OR for patients with a higher BMI requiring 
IMV (56% vs. 28%, OR: 3.3, 95% CI: 1.6 - 7.0, P = 0.002) 
and upgrade to ICU (46% vs. 28%, OR: 2.2, 1.07 - 4.6, P = 
0.04) were significantly higher compared to patients with a 
lower BMI. Similarly, patients with a higher BMI had higher 
in-hospital mortality (21% vs. 9%, OR: 3.2, 95% CI: 1.3 - 8.2, 
P = 0.01) compared to patients with a normal BMI. Despite 
a numerical advantage in the lower BMI group, there was no 
significant difference between the two groups in terms of the 
need for dialysis (5% vs. 13%, OR: 3.8, 13% vs. 4%, 1.1 - 
14.1, P = 0.07).
A multivariate regression model was used to adjust the 
observed ORs for baseline comorbidities and medications, in-
cluding DM, HTN, CKD, CAD, use of AC at home, HCQ, 
tocilizumab, steroids and therapeutic AC during the hospital 
stay. The aORs mirrored the overall findings of unadjusted 
ORs with one exception. In contrast to the unadjusted OR, 
there was no significant difference in the rate of an upgrade to 
the ICU for patients with high and low BMI groups (aOR: 1.7, 
0.7 - 3.9, P = 0.17) (Fig. 3, Table 3).
Figure 3. Mean BMI values and number of patients across different in-hospital endpoints. BMI: body mass index.
Table 2.  Mean BMI Values Across Different Outcomes and Medication Groups
Outcome N BMI, mean ± SD Mean difference (95% CI) P value
Alive 155 30.2 ± 8.9 -5.15 (-9.5 to -7.4) 0.022
Death 21 35.4 ± 13.8
No dialysis 166 30.6 ± 9.8 -3.3 (-9.6 to 2.90) 0.29
Dialysis 10 34.0 ± 6.6
No ventilator 116 29.2 ± 8.4 -4.7 (-7.7 to -1.7) 0.002
Ventilator 60 33.9 ± 11.2
No upgrade 120 30.1 ± 9.9 -2.2 (-5.3 to 0.82) 0.14
Upgrade 56 32.3 ± 9.1
No AC 142 30.3 ± 9.5 -2.7 (-6.4 to 9.0) 0.14
AC 34 33.1 ± 6.1
No steroids 146 29.8 ± 8.6 -5.8 (-9.6 to -2.09) 0.002
Steroids 30 35.7 ± 13
No tocilizumab 144 30.5 ± 10.3 -1.45 (-5.2 to 2.3) 0.44
Tocilizumab 32 32.0 ± 6.3
No HCQ 32 27.2 ± 6.17 -4.3 (-8.09 to -0.68) 0.21
HCQ 144 31.6 ± 10.20
SD: standard deviations; CI: confidence interval; BMI: body mass index; HCQ: hydroxychloroquine; AC: anticoagulation.
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Discussion
Our study reveals that obesity is an independent risk factor for 
worse outcomes in COVID-19. Patients with a BMI > 35 kg/
m2 have three times higher odds for mortality and respiratory 
complications necessitating IMV compared to patients with a 
BMI lower than 34.9 kg/m2. There were substantial differences 
in the BMIs of patients who survived COVID-19 compared 
with those who succumbed to the disease (5.15, P = 0.02). A 
similar difference was observed in patients who required me-
chanical ventilation versus those in whom the disease severity 
did not progress as far (4.7, P = 0.002). Although patients with 
a higher BMI seemed to have a greater need for higher-level 
care, this trend could have been driven by multiple comorbidi-
ties as evidenced by an identical aOR (P = 0.14). Partly con-
tributing to this was also the higher tendency to opt for “com-
fort measures” or “no escalation of care” in obese patients, 
precluding an upgrade to the ICU in patients whose clinical 
condition otherwise would require it.
Obesity has traditionally been linked to severe respiratory 
infections. Previous epidemiological and clinical studies have 
shown that obesity increases the rate of hospitalization as well 
as death in patients with influenza type A (H1N1) [6-8]. These 
findings were later validated by Kwong et al and Maccioni et 
al, who also reported that obese patients were more likely to 
get hospitalized due to upper and lower respiratory tract com-
plications [7, 8]. With the recent outbreak, early evidence from 
China showed a similar association between obesity and COV-
ID-19. Cai et al observed that overweight and obese patients 
had two-fold higher odds of suffering from severe pneumo-
nia when controlled for potential confounders [9]. In line with 
these studies, our study demonstrated even higher odds for se-
vere respiratory compromise requiring IMV when adjusted for 
baseline comorbidities.
It is believed that both mechanical and inflammatory 
mechanisms contribute to obesity-related adverse outcomes in 
COVID-19. Obesity results in reduced ventilation by reduc-
ing diaphragmatic excursion and limiting chest wall mobility. 
Additionally, adipose tissue plays a role in immunological 
response by producing a variety of adipokines and pro-in-
flammatory cytokines, including leptin, interleukins 4 and 6, 
interferon, tumor necrosis factor, adiponectin, resistin, and 
visfatin [10, 11]. While our study revealed an increased risk 
for IMV and mortality, surprisingly, the inflammatory markers 
including mean D-dimer (P = 0.99), ferritin (P = 0.81) and CRP 
(P = 0.31) on both day 1 and day 7 of hospitalizations were 
not impacted by higher BMI. These findings indicate either 
that the respiratory complications and mortality in obesity in 
COVID-19 patients could be independent of inflammation or 
that inflammatory markers lag behind the said complications. 
It may be that more than inflammation, a higher resistance in 
their airways, lower lung volumes, and weaker respiratory 
muscles due to obesity play a major role in respiratory compli-
cations in COVID-19.
Apart from the above-mentioned mechanisms, studies 
have shown that viral replication rates are higher in the cells of 
patients who are obese compared to those with normal BMI, 
contributing to a higher susceptibility to viral infection [12, 
13]. Studies done to assess the immune response to vaccina-
tion have also shown a consistently poorer response in people 
with obesity [14]. This lends further credence to the theory that 
adipose tissue driven immunological changes attenuate an ef-
fective response to viral infection. A previous analysis of 124 
ICU patients with COVID-19 in a French hospital showed a 
direct correlation of BMI with IMV (P < 0.01), the requirement 
being highest in those with BMI > 35 kg/m2 (85.7%) [15]. Our 
findings not only show a similar increase in the need for IMV, 
but also highlight three-fold higher odds of in-hospital mortal-
ity in patients with high BMI. The association is independent 
of age, comorbidities, or therapeutic strategies employed.
We believe that the collision of the COVID-19 pandemic 
with the ongoing endemic of obesity poses major clinical chal-
lenges for physicians, and has significant logistical implica-
tions for the healthcare sector at large. North America and 
Western Europe are not only the current hubs of COVID-19 
but also have the highest prevalence of obesity [1]. Providing 
intensive care, with its attendant high resource consumption, 
to these patients represents a challenge for healthcare systems 
in these regions. The need for more bariatric beds, mechani-
cal ventilators, expertise in intubation and skilled nursing staff 
(required to position and transport obese patients) rises with 
each passing day. Severe respiratory complications along with 
difficulties faced by obese patients during diagnostic imag-
ing further compromise the medical care of such patients. Our 
study highlights the higher risk of adverse outcomes in this pa-
Table 3.  Unadjusted and Adjusted Odds Ratios of Outcomes in Normal and Obese BMI Groups
Outcomes N BMI < 34 BMI > 35 Unadjusted odds P value Adjusted odds ratio (aOR) P value
Vent 60 38 (28%) 22 (56%) OR 3.3 (1.6 - 7.0) 0.002 aOR 2.6 (1.17 - 6.1) 0.01
No vent 116 99 (72%) 17 (44%)
Upgrade 56 38 (28%) 18 (46%) OR 2.2 (1.07 - 4.6) 0.04 aOR 1.7 (0.7 - 3.9) 0.17
No upgrade 120 99 (72%) 21 (54%)
Dialysis 10 5 (4%) 5 (13%) OR 3.8 (1.1 - 14.1) 0.07 aOR 3.6 (0.8 - 15.7) 0.08
No dialysis 166 132 (96%) 34 (87%)
Died 23 13 (9%) 10 (21%) OR 3.2 (1.3 - 8.2) 0.01 aOR 2.9 (1.1 - 6.0) 0.02
Alive 153 124 (91%) 29 (79%)
BMI: body mass index.
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tient population, allowing physicians to not only anticipate and 
prognosticate these unfortunate outcomes but also to inform 
decisions about resource allocation.
Limitations
The major limitation of our study was the small sample size from 
a single institution. Although the retrospective cohort study de-
sign used can estimate associations only; similar to a prospective 
design, our study does have the strength of certainty regarding 
the temporal sequence of the exposures and outcomes. Likely 
due to small sample size, CIs were wide and the threshold of 
statistical significance could not be achieved for multiple com-
parisons. Although the overall findings were adjusted for co-
variates, including baseline comorbidities and medications, the 
impact of unmeasured confounders such as initiation of several 
complementary therapies at the treating physician’s discretion, 
could not be determined. Moreover, by excluding patients still in 
the hospital, the case fatality ratio in our study cannot reflect the 
true mortality of COVID-19. Despite the limited sample size, by 
adjusting adult patients with the confirmed disease, we believe 
our population is representative of the real-world cohort.
Conclusions
In patients with confirmed COVID-19, morbid obesity appears 
to be an independent risk factor of high in-hospital mortality 
and the need for IMV.
Supplementary Material
Suppl 1. Mean BMI values across in-hospital complications.
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